Q-VANT Biosciences is a privately-held company that has solved the supply chain problem of QS-21 and other quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets.
The company’s disruptive technology increases the potential for sustainable QS-21 supply by a factor of 1,000 resulting in a possible annual production capacity exceeding 20 billion pharmaceutical doses.
Executive Team
Doug Klaiber
Chief Executive Officer
More than 25 years of start-up, technology and pharmaceutical experience. Former CEO of Decas Botanical Synergies and Naturex-DBS.
Bruce Forrest, MD & MBA
Chief Scientific Officer
Former SVP R&D Pfizer/Wyeth Vaccines. More than 25 years of experience in vaccine & adjuvant development and commercialization.
Hans Konsens
Chief Operating Officer
More than 10 years of experience in quillaja extract process development, supply chain, manufacturing, R&D and commercialization. Former Founder and Managing Director of Chile Botanics–Naturex, global leader in the Quillaja Extracts markets.
Jack Love, Ph.D.
VP of Regulatory Affairs
Former AVP Regulatory Affairs for Pfizer Vaccines. More than 25 years of pharmaceutical experience including new vaccine development and regulatory approvals.
Juan José Albarrán
Chief Commercial Officer
More than 10 years of experience in quillaja extract process development, supply chain, manufacturing, R&D and commercialization. Former Founder and Managing Director of Chile Botanics–Naturex, global leader in the Quillaja Extracts markets.
Stein Lokstad
VP of Business Development
Former GM of Brenntag Biosector vaccine adjuvant company. More than 25 years pharmaceutical experience including 10 years developing and selling vaccine adjuvants.
Operations
Matthieu Privat
Business Development Manager
More than 10 years of experience in molecular biology and quillaja saponin marketing, supply chain. Former Deputy Commercial Manager of Desert King.
Scientific Team
Elias Atala, Ph.D.
Technology Manager
Expert in chromatographic process development with 10 years of experience in R&D chemistry, purification and application of quillaja saponins.
Francisco Ibañez, Ph.D.
Vaccine and Adjuvant Specialist Developer
Biochemist specialized in immunology with vast academic and professional experience in the development of antiviral drugs, vaccines against respiratory viruses, and adjuvants.
Cristobal Silva
R&D Specialist
R&D expert in the industrial field of botanical extracts including purification, analytical quantification and product formulation.